Medication info
Crestba Tablet 20mg (Rosuvastatin Calcium)

Crestba Tablet 20mg (Rosuvastatin Calcium)

Prescription medicationTabletOral
Ingredient · strength
Rosuvastatin Calcium›20.8mg / 1 tablet
Manufacturer / importer
HanKook Hyutech Pharmaceutical Co., Ltd.
Appearance
Pink round film-coated tablet
Packaging
30 tablets/bottle, 100 tablets/bottle
Approval status
Active

MFDS item code 201400840 · Approved 2014.02.24 · Insurance code 649102280

Summary

Main use
Improvement of dyslipidemia, inhibition of atherosclerosis progression, and prevention of cardiovascular disease
Who takes it
Adults · Children
Adult dose
1. Primary hypercholesterolemia (type IIa, including heterozygous familial hypercholesterolemia), mixed dyslipidemia (type IIb), primary dysbetalipoproteinemia (type III), and homozygous familial hypercholesterolemia Patients should follow a standard cholesterol-lowering diet before and during treatment with this medicine and continue it throughout the treatment period. This medicine may be taken at any time of day, with or without food. The initial dose is 5 milligrams once daily. If a greater reduction in LDL cholesterol is required, the dose may be adjusted to the maintenance dose. The maintenance dose is 10 milligrams once daily, which is adequate for most patients. The maintenance dose should be adjusted appropriately at intervals of 4 weeks or longer according to LDL cholesterol levels, treatment goals, and the patient's response. The dose may be increased to a maximum of 20 milligrams once daily. 3. Elderly patients: No dose adjustment is necessary. 4. Patients with renal impairment: No dose adjustment is necessary in patients with mild or moderate renal impairment. Do not administer to patients with severe renal impairment. Particular caution is required when administering 20 mg of this medicine to patients with moderate renal impairment. 5. Patients with hepatic impairment: No increase in systemic exposure to rosuvastatin was observed in patients with a Child-Pugh score of 7 or less, but an increase was observed in patients with a Child-Pugh score of 8 or 9. Renal function testing should be considered in these patients. There is no experience with administration to patients with a Child-Pugh score greater than 9. Do not administer this medicine to patients with active liver disease. 6. Race: Because systemic exposure to this medicine is increased in Asian patients, the recommended initial dose is 5 milligrams. Administration of the 40-milligram dose is contraindicated. 7. Patients predisposed to myopathy: The recommended initial dose for patients predisposed to myopathy is 5 milligrams. Administration of the 40-milligram dose is contraindicated in some of these patients.
Child dose
2. Pediatric patients with heterozygous familial hypercholesterolemia (ages 10 to 17 years): The usual dose range is 5 milligrams to 20 milligrams once daily. (There are no clinical data on doses greater than 20 milligrams in pediatric patients.) The dose should be adjusted individually according to the recommended treatment goal for each patient. The dose should be adjusted at intervals of 4 weeks or longer. Children under 10 years of age: Safety and efficacy have not been established.

Ingredients

Manufacturer
HanKook Hyutech Pharmaceutical Co., Ltd.

Efficacy & effects

Improvement of dyslipidemia, inhibition of atherosclerosis progression, and prevention of cardiovascular disease

  • Primary hypercholesterolemia
  • heterozygous familial hypercholesterolemia
  • mixed dyslipidemia
  • homozygous familial hypercholesterolemia
  • hypercholesterolemia
  • heterozygous familial hypercholesterolemia
  • primary dysbetalipoproteinemia
  • elevated high-sensitivity C-reactive protein
  • hypertension
  • low HDL-cholesterol levels
  • smoking
  • family history of early coronary heart disease
View approved original text

This medication is used as an adjunctive treatment when diet and exercise alone are insufficient for patients with primary hypercholesterolemia and mixed dyslipidemia. It is particularly beneficial when used in conjunction with other lipid-lowering therapies for patients with homozygous familial hypercholesterolemia. This drug effectively lowers total cholesterol and LDL-cholesterol levels, thereby slowing the progression of atherosclerosis. It is also appropriate for pediatric patients with heterozygous familial hypercholesterolemia aged between 10 and 17 years, to be used as an adjunct to diet when specific criteria are met. Additionally, it is used as an adjunct to diet for patients with primary dysbetalipoproteinemia. Finally, this drug helps reduce the risk of stroke, myocardial infarction, and arterial revascularization procedures in men over 50 years of age and women over 60 years of age with elevated high-sensitivity C-reactive protein levels. Overall, it is used to improve cardiovascular health.

How to take

Adult dose

1. Primary hypercholesterolemia (type IIa, including heterozygous familial hypercholesterolemia), mixed dyslipidemia (type IIb), primary dysbetalipoproteinemia (type III), and homozygous familial hypercholesterolemia Patients should follow a standard cholesterol-lowering diet before and during treatment with this medicine and continue it throughout the treatment period. This medicine may be taken at any time of day, with or without food. The initial dose is 5 milligrams once daily. If a greater reduction in LDL cholesterol is required, the dose may be adjusted to the maintenance dose. The maintenance dose is 10 milligrams once daily, which is adequate for most patients. The maintenance dose should be adjusted appropriately at intervals of 4 weeks or longer according to LDL cholesterol levels, treatment goals, and the patient's response. The dose may be increased to a maximum of 20 milligrams once daily. 3. Elderly patients: No dose adjustment is necessary. 4. Patients with renal impairment: No dose adjustment is necessary in patients with mild or moderate renal impairment. Do not administer to patients with severe renal impairment. Particular caution is required when administering 20 mg of this medicine to patients with moderate renal impairment. 5. Patients with hepatic impairment: No increase in systemic exposure to rosuvastatin was observed in patients with a Child-Pugh score of 7 or less, but an increase was observed in patients with a Child-Pugh score of 8 or 9. Renal function testing should be considered in these patients. There is no experience with administration to patients with a Child-Pugh score greater than 9. Do not administer this medicine to patients with active liver disease. 6. Race: Because systemic exposure to this medicine is increased in Asian patients, the recommended initial dose is 5 milligrams. Administration of the 40-milligram dose is contraindicated. 7. Patients predisposed to myopathy: The recommended initial dose for patients predisposed to myopathy is 5 milligrams. Administration of the 40-milligram dose is contraindicated in some of these patients.

Child dose

2. Pediatric patients with heterozygous familial hypercholesterolemia (ages 10 to 17 years): The usual dose range is 5 milligrams to 20 milligrams once daily. (There are no clinical data on doses greater than 20 milligrams in pediatric patients.) The dose should be adjusted individually according to the recommended treatment goal for each patient. The dose should be adjusted at intervals of 4 weeks or longer. Children under 10 years of age: Safety and efficacy have not been established.

Precautions

This medication should not be administered to certain patients, such as those with an allergy to this drug, severe liver disease, or muscle disorders, as well as those taking certain medications, severely impaired renal function patients, and women who are pregnant or breastfeeding. It is important to regularly monitor liver function and muscle condition before and during treatment, especially for patients with a history of liver disease or who consume alcohol heavily. If symptoms like muscle pain or weakness occur, patients should notify healthcare professionals immediately, and treatment may need to be discontinued in severe cases. This medication contains lactose, so patients with lactose intolerance should avoid taking it. Additionally, this drug may interact with other medications, so patients should inform their healthcare provider about any other medications they are taking, especially with certain antiviral drugs, immunosuppressants, and fibrate medications. Women with childbearing potential should use appropriate contraceptive methods, and those who are pregnant or breastfeeding should avoid taking it. In cases of overdose, there is no specific antidote, and symptomatic treatment should be initiated while monitoring liver function and muscle enzyme levels. This drug may cause side effects such as dizziness, so caution is advised when driving or operating machinery. Finally, rare but serious side effects such as interstitial lung disease or severe skin reactions may occur with long-term use, so patients should consult healthcare professionals immediately if any unusual symptoms appear.

Side effects

Allergic reactions including angioedema, diabetes, headache, dizziness, constipation, nausea, abdominal pain, pancreatitis, itching, rash, urticaria, myalgia, myopathy, rhabdomyolysis, weakness, polyneuropathy, memory loss, peripheral neuropathy, myasthenia gravis, cough, dyspnea, diarrhea, ocular weakness, thrombocytopenia, jaundice, hepatitis, increased transaminases, Stevens-Johnson syndrome, eosinophilia and systemic symptoms associated drug reaction syndrome, lichenoid drug eruption, lupus-like syndrome, muscle rupture, arthralgia, immune-mediated necrotizing myopathy, hematuria, edema, depression, sleep disorders, sexual dysfunction, gynecomastia, fatal and non-fatal liver failure, cognitive impairment, increased ALT, chest pain, muscle cramps, gout, erectile dysfunction, increased AST, numbness, paresthesia, chest discomfort, anorexia, abdominal distension, syncope, generalized pain, fatigue

Not everyone experiences these, and they can vary from person to person.

Storage

This medication may be sensitive to air and moisture, so it must be stored in a tightly closed container. It is recommended to maintain the storage temperature between 1 degree to 30 degrees Celsius. This will help preserve the medication's effectiveness and safety over time.

Appearance and packaging

Appearance

Pink round film-coated tablet

Package unit

30 tablets/bottle, 100 tablets/bottle

Same-ingredient medicines

Even with the same ingredient, strength, dosage form and how it is taken can differ.

Even with the same ingredient, the dose and directions can differ by strength and dosage form. Talk to a doctor or pharmacist before switching from a medication you are already taking.

Questions about this medicine

No questions yet.

For anything that needs medical judgment, consult a doctor or pharmacist.

Related searches

Search tags

Suggested searches

This drug information is based on data provided by the Korea Ministry of Food and Drug Safety.
Consult a doctor or pharmacist for accurate dosage, administration, and usage instructions.